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IMPORTANCE Early melanoma detection strategies include skin self-examination (SSE),
physician skin examination (PSE), and promotion of patient knowledge about skin cancer.
OBJECTIVE To investigate the association of SSE, PSE, and patient attitudes with the
detection of thinner superficial spreadingmelanoma (SSM) and nodular melanoma (NM),
the latter of which tends to elude early detection.
DESIGN, SETTING, AND PARTICIPANTS This cross-sectional, questionnaire-based,multicenter
study identified patients with newly diagnosed cutaneous melanoma at 4 referral hospital
centers in the United States, Greece, and Hungary. Among 920 patients with a primary
invasive melanoma, 685 patients with SSM or NM subtype were included.
INTERVENTIONS A standardized questionnaire was used to record sociodemographic
information, SSE and PSE practices, and patient perceptions in the year prior to diagnosis.
MAIN OUTCOMES ANDMEASURES Data were analyzed according to histologic thickness,
with a 2-mm cutoff for thinner SSM and NM.
RESULTS Of 685 participants (mean [SD] age, 55.6 [15.1] years; 318 [46%] female), thinner
melanomawas detected in 437 of 538 SSM (81%) and in 40 of 147 NM (27%). Patients who
routinely performed SSE weremore likely to be diagnosed with thinner SSM (odds ratio [OR],
2.61; 95% CI, 1.14-5.40) but not thinner NM (OR, 2.39; 95% CI, 0.84-6.80). Self-detected
clinical warning signs (eg, elevation and onset of pain) were markers of thicker SSM and NM.
Whole-body PSE was associated with a 2-fold increase in detection of thinner SSM (OR, 2.25;
95% CI, 1.16-4.35) and thinner NM (OR, 2.67; 95% CI, 1.05-6.82). Patient attitudes and
perceptions focusing on increased interest in skin cancer were associated with the detection
of thinner NM.
CONCLUSIONS AND RELEVANCE Our findings underscore the importance of complementary
practices by patients and physicians for the early detection of melanoma, including regular
whole-body PSE, SSE, and increased patient awareness.
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I n patients with cutaneous melanoma, tumor thickness isthe strongest independent predictor of survival. Twenty-year survival approaches 96% in patients with thin mela-
noma (Breslow thickness ≤1 mm), while thicker melanomas
are associated with higher mortality risk.1,2 In 6 populations
of European heritage, predictive models suggest continuous
increases in incidence of cutaneous melanoma through
2031, which highlights the need for melanoma control
strategies.3
Widespreadearlydetectioneffortshavecontributed to the
rapidly rising incidence of thin melanoma in Australia,4 the
United States,5 andEurope.6,7 Factors associatedwith the de-
tection of thin melanoma (≤1 mm) in a multicenter observa-
tional US study showed that patients who underwent a full-
body physician skin examination (PSE) in the year before
diagnosiswere twiceas likely tohave thinmelanoma.8 Inasub-
sequent study of Greek patients, thin melanoma was associ-
ated with female sex, married status, and performing careful
skin self-examination (SSE).9 In all of these studies, however,
there are limited data correlating these diagnostic and behav-
ioral factors with different histologic subtypes of cutaneous
melanoma, including the most common, superficial spread-
ing melanoma (SSM), and the most commonly fatal, nodular
melanoma (NM).
In a population-based, prospective melanoma registry
studyamong26736patientswith thinmelanoma (<0.75mm),
NMsubtypewas among the factors associatedwith increased
riskofdeath.2,10BecauseNMaccounts for40%to50%ofmela-
nomaswithBreslow thickness greater than2mm11,12 and is of-
tendescribedas a rapidly growing tumor,13 theremaybeanar-
rower window for detection of NM in its thinner phases. In
general, NM exhibits distinct characteristics from SSM: it oc-
curs more frequently in older men,11,14 has higher growth ki-
netics and mitotic rate, and presents with clinical character-
istics that tend to elude early detection (eg, amelanosis,
symmetry, andborder regularity).11-13,15,16 Fewstudieshaveas-
sessed factors associated with the detection of thinner NM
(≤2 mm).12,14,17,18
The aim of this multicenter study was to investigate skin
examination andbehavioral patterns in patientswith thinner
vs thicker melanoma and examine how they may differ be-
tween NM and SSM subtypes.
Methods
Participation Centers and Patients
Pooled data were collected from 3 studies that used the same
protocol among 4 dermatology-based melanoma referral
centers at Stanford University and the University of Michi-
gan in the United States,8 at the University of Athens and
collaborating centers in Greece,9 and at the University of
Szeged in Hungary from January 2015 to December 2015.
Institutional review board and ethics approval and informed
patient consent were obtained at all sites. The participants
were consecutive, newly diagnosed, predominantly Cauca-
sian patients 18 years or older with primary invasive mela-
noma. As the study aimed to explore differences in tumor
thickness at diagnosis between NM and SSM, only patients
with these histopathological subtypes were included.
Patients with melanoma in situ, multiple primary melano-
mas, or noncutaneous melanoma were excluded.
Patient Interview and Data Collection
All questions concerned the year before diagnosis. The same
structured questionnaire was used, based on the study by
Swetter et al,8 after translation into Greek and Hungarian. A
sample of randomly selected questions were translated back
toEnglish to validate the accuracy of the translation. Theder-
matologist or an appropriately trainedphysician, nurse, or re-
search assistant administered the questionnaires. Investi-
gated variables included demographic information (age, sex,
education,andmarital status);phenotypiccharacteristics (skin
color and skin reaction to first sun exposure during summer);
and melanoma history (previous melanoma and family his-
tory of melanoma in a first-degree relative). Questionnaire
items included attitudes and perceptions reflecting mela-
noma awareness, SSE and PSE practices, and mode of mela-
noma discovery.
We categorized SSE in 3 ways as previously described in
the study by Pollitt et al19: (1) routine examination of any of 13
specific body areas, (2) frequency of mole examination, and
(3) useof apicture aid illustrating amelanoma tumor. The first
measure asked patients to identify which of 13 areas of their
skin they routinely examined.Thismeasurewas alsodichoto-
mized by whether patients routinely examined their skin on
some and/or all areas or no areas. The second measure as-
sessed the frequency with which patients carefully exam-
ined their moles, categorized as every 1 to 2 months, every 6
months,everyyear,andnever.Thethird itemassessedwhether
patients ever used a picture of melanoma to help them look
at their skin.
Patients were asked about self-detected clinical changes
in the lesion that turned out to be melanoma (color, border,
thickness/elevation, pain, itching, bleeding, different than it
used to be), whether they could easily see the lesion, and
whether they noticed a change in any of their moles.
Physician skin examination in the year before diagnosis
was assessed, as previously described in the study by
Swetter et al,8 by asking patients whether they had a usual
Key Points
Question What examination practices and patient attitudes are
associated with the detection of thinner nodular melanoma (NM)
and superficial spreadingmelanoma (SSM)?
Findings In this cross-sectional pooled analysis of 685 patients,
whole-body physician skin examination was associated with
thinner NM and SSM, while skin self-examination was associated
with thinner SSM only. Increased skin cancer awareness was
associated with thinner NM.
Meaning Because NM is typically detected at greater than 2mm
thickness, understanding these factors for earlier detectionmay
improve survival.
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place to go when sick or in need of health advice, whether
they had a physician for routine care, whether a physician
examined their skin for cancer during any visits, why the
physician examined their skin for cancer, and whether the
physician examined the patient’s whole skin or just a par-
ticular lesion.
In addition, 1 composite variable assessed successful SSE
as self-detection of thinner melanoma in patients who regu-
larlyperformedSSE.AsecondvariableassessedsuccessfulPSE
as the detection of thinner melanoma by physicians in pa-
tients who received a PSE.
Clinical examination of patients was conducted by a der-
matologist who provided the count of total nevi and clini-
cally atypical (dysplastic) nevi. Anatomic location and histo-
pathological characteristics of melanoma were classified
according to the 2009 American Joint Committee on Cancer
melanomastagingandclassificationguidelines.1Acceptedcri-
teria for histopathologic classification of SSM vs NM subtype
were used.20
For thinner NM, a cutoff of 2 mm or less was used be-
cause only 4 NM in the entire data set were diagnosed with a
thickness of 1mmor less,whichprecluded any reliable analy-
sis of the examined factors. For thinner SSM, theprimary out-
come of Breslow thickness of less than or equal to 2 mmwas
used to define thin melanoma to be consistent with the defi-
nition of thinner NM. Thinner SSMwere further investigated
in a secondary analysis with the use of a cutoff of less than or
equal to 1 mm, while maintaining the cutoff of 2 mm or less
for thinner NM.
Statistical Analysis
Descriptive statistics for the characteristics of patients were
calculated. Continuous data are presented as mean (SD) for
normally distributed variables and were compared using the
student t test. Categorical data are presented as numbers
and frequencies.
Association between the 2 melanoma subtypes and each
variable was investigated by exploratory analysis with a χ2
test or a Fisher exact test, as appropriate, and with univari-
ate logistic regression analysis. To investigate the association
of thinner melanoma with every variable, multiple logistic
regression analysis was carried out with different models for
the outcomes of NM or SSM melanoma subtypes, including
statistically significant variables from the univariate analy-
sis. Multivariate analysis for SSM was adjusted for age, sex,
and education, and multivariate analysis for NM included
patient age and sex, as no factors were statistically signifi-
cant in the univariate analysis for thinner NM. Adjustment
for country (US, Greece, or Hungary) showed similar results
for NM and SSM, so this variable was not included in the
final parsimonious model (data not shown).
As the detection of thinner melanoma was the outcome
of this study, the odds ratios are reported as the odds of thin-
nermelanoma comparedwith those of thickermelanoma.All
P values were 2-sided, and the significance level was P < .05.
Analyses were carried out using STATA statistical software,
version 13 (StataCorp).
Results
Patient andMelanoma Characteristics
Overall, therewere 920 patients with a cutaneousmelanoma
diagnosis.Of these,235patientswereexcluded(207withmela-
noma of other histological types, and 28 formissing or “don’t
know” answers in variables of interest). Exclusion rates per
countrywere as follows:UnitedStates, 30%;Greece, 18%; and
Hungary, 18%. Included patients per countrywere as follows:
395 fromtheUnitedStates, 165 fromGreece, and125 fromHun-
gary. In the total of 685 included patients with SSM and NM,
437 of 538 (81.0%) had thinner SSM (≤2 mm) and 40 of 147
(27.2%) had thinner NM (≤2 mm) (Figure).
Themean (SD)ageofparticipantswas55.6 (15.1) years, and
318of685 (46%)were female. Sociodemographicvariablesand
nevus count bymelanoma thickness are presented inTable 1.
In comparisonwithpatientswith SSM,patientswithNMwere
older (meanage, 58.79yearsvs54.71years;P = .004)andmore
likely tobemale (62%vs51%;P = .02).For thinnervs thickNM,
therewereno significant associations by age, sex,marital sta-
tus, education, or location of melanoma. Phenotypic factors
suchas skincolor,numberofnevi, andnumberof atypicalnevi
were not associated with melanoma thickness.
Clinical and Behavioral Traits Associated
With the Detection of Thinner NM
Routine SSE of some (≥1) or all body parts was not associated
with thinner NM (odds ratio [OR], 2.39; 95% CI, 0.84-6.80).
Therewereno self-detected clinical changes of the lesion that
Figure. Flowchart of PatientsWithMelanoma Included in the Study
920 Assessed for eligibility
566 From United States
202 From Greece
152 From Hungary
538 Diagnosed with SSM
317 From United States
122 From Greece
99 From Hungary
147 Diagnosed with NM
78 From United States
43 From Greece
26 From Hungary
685 Included
235 Excluded
207 Did not meet inclusion criteria
67 Lentigo maligna melanoma
32 Acral lentiginous melanoma
26 Desmoplastic melanoma
82 Other or unknown 
histologic subtype
Excluded for other reasons28
Of 920 patients assessed for eligibility, 685 were included in the study.
Participants were consecutive, newly diagnosed, predominantly Caucasian
patients 18 years or older with primary invasive melanoma. As the study aimed
to explore differences in tumor thickness at diagnosis between nodular
melanoma (NM) and superficial spreadingmelanoma (SSM), only patients with
these histopathological subtypes were included. Of 685 patients, 147 were
diagnosed with NM, and 538were diagnosed with SSM.
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were associated with the detection of thinner NM, except for
patientswho reported noticing a change in any of theirmoles
(OR, 2.62; 95% CI, 1.21-5.67) (Table 2).
In the multivariate analysis, receiving a PSE was associ-
atedwith thedetection of thinnerNM (OR, 2.21; 95%CI, 1.04-
4.69), especially when the physician conducted a whole-
bodyskinexamination (OR,2.67;95%CI, 1.05-6.82) rather than
examining a particular lesion. For patients with NM, having
been told by their doctor that theywere at risk for skin cancer
was associated with thinner NM detection (OR, 5.32; 95% CI,
2.26-12.53).When PSEwas part of the doctor’s routine physi-
cal examination, it was not associated with the detection of
thinner NM (OR, 2.26; 95%CI, 0.81-6.30); it only reached sig-
nificancewhenPSEwaspromptedby increasedpatientorphy-
sician concern or awareness (Table 3).
ThinnerNMdetectionwassignificantlyassociatedwithpa-
tients taking an interest in reading about skin cancer detec-
tion (OR, 4.20; 95%CI, 1.62-10.87), thinking it was important
to look at skin for signs ofmelanoma (OR, 5.52; 95%CI, 2.09-
14.50), andbelieving itwas important tohaveahealthcarepro-
fessional examine the skin for signs of melanoma (OR, 4.10;
95% CI, 1.65-10.16) (Table 4).
Patients who were comfortable having a family member
lookat theirmoles andwere comfortableundressing for a skin
examination by a health care professional had an estimated
6-fold to 7-fold increased probability of being diagnosedwith
thinner NM compared with thick NM. Patients who never
thoughtof themselves at risk formelanomawereathigher risk
for thicker NM (Table 4).
Clinical and Behavioral Traits Associated
With the Detection of Thinner SSM
Routine SSEof some (≥1) or all bodypartswas significantly as-
sociatedwith thinner SSM (OR, 2.61; 95%CI, 1.14-5.40). Thin-
ner SSMwasassociatedwith the regular SSEofbodyareas that
were easy to self-examine (face, front of legs, chest, stomach,
Table 1. Basic Characteristics byMelanoma Thickness in PatientsWith NMor SSM
Characteristic
Patients With NM (n = 147) Patients With SSM (n = 538)
Tumor
≤2 mm
Tumor
>2 mm P Value
Tumor
≤2 mm
Tumor
>2 mm P Value
Patients, No. (%) 40 (27) 107 (73) 437 (81) 101 (19)
Age, mean (SD), y 58 (15) 59 (16) .72 53 (14) 61 (16) <.001a
Sex, No. (%) .50 .25
Male 23 (25) 68 (75) 219 (79) 57 (21)
Female 17 (30) 39 (70) 218 (83) 44 (17)
Marital status, No. (%)b .09 .62
Married 21 (22) 74 (78) 316 (82) 70 (18)
Widowed/single
never-married/divorced
or separated
18 (35) 33 (65) 116 (80) 29 (20)
Education, No. (%)c .45 <.001a
Associate’s degree/graduated
from college/postgraduate
23 (30) 53 (70) 277 (87) 42 (13)
Secondary/high school 17 (25) 52 (75) 156 (73) 58 (27)
Skin color, No. (%) .30 .82
Very fair/fair 36 (29) 89 (71) 376 (81) 86 (19)
Dark/olive/very dark 4 (18) 18 (82) 61 (80) 15 (20)
No. of nevi, No. (%) .22 .49
0-20 22 (23) 75 (77) 270 (81) 64 (19)
20-50 12 (38) 20 (63) 100 (79) 26 (21)
>50 6 (33) 12 (67) 67 (86) 11 (14)
No. of atypical nevi, No. (%) .70 .94
0 19 (24) 61 (76) 226 (82) 49 (18)
1-5 8 (32) 17 (68) 97 (84) 19 (16)
>6 5 (28) 13 (72) 66 (83) 14 (17)
Histopathologic ulceration,
No. (%)d
.002a,e <.001a,e
No 25 (39) 39 (61) 382 (88) 51 (12)
Yes 12 (16) 65 (84) 53 (53) 47 (47)
Unknown 2 (50) 2 (50) 1 (33) 2 (67)
Location of melanoma, No. (%)f .91 .05
Head/neck 8 (29) 20 (71) 39 (75) 13 (25)
Trunk 14 (24) 44 (76) 199 (84) 37 (16)
Upper extremity 6 (30) 14 (70) 81 (86) 13 (14)
Lower extremity 12 (30) 28 (70) 110 (81) 36 (25)
Abbreviations: NM, nodular
melanoma; SSM, superficial
spreadingmelanoma.
a Statistically significant.
b Eight missing values.
c Sevenmissing values.
d Four missing values.
e Fisher exact test.
f Elevenmissing values.
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Table 2. Multivariate Logistic Regression Analysis of Patient Skin Self-Examination Practices
AssociatedWithMelanoma Thickness in PatientsWith NMor SSM
Variable
Patients With NM (n = 147) Patients With SSM (n = 538)
Patients,
No.
Tumor ≤2 mm,
OR (95% CI)a P Value
Patients,
No.
Tumor ≤2 mm,
OR (95% CI)b P Value
Who first noticed the lesion that
turned out to
be melanoma?c
Patient 92 1.19 (0.47-3.02) .71 265 0.66 (0.39-1.13) .13
Medical provider 20 1.77 (0.52-6.01) .36 111 2.48 (1.14-5.40) .02d
Spouse/family/friend/other 35 1 [Reference] 157 1 [Reference]
Routine self-examinatione
Examination of
some/all skin
107 2.39 (0.84-6.80) .10 400 2.61 (1.60-4.25) <.001d
No examination 34 1 [Reference] 125 1 [Reference]
Body areas routinely examined
Areas that are easy
to self-examinef
Yes 106 2.42 (0.85-6.90) .10 391 2.59 (1.58-4.23) <.001d
No 34 1 [Reference] 125 1 [Reference]
Areas that are difficult
to self-examineg
Yes 79 2.61 (0.88-7.72) .08 326 2.82 (1.69-4.71) <.001d
No 34 1 [Reference] 125 1 [Reference]
Areas that are very difficult
to self-examineh
Yes 32 1.59 (0.44-5.73) .48 157 3.28 (1.73-6.21) <.001d
No 34 1 [Reference] 125 1 [Reference]
If patient noticed changes that
turned out to be melanoma,
what were those changes?
Change in border
Yes 26 0.28 (0.08-1.01) .05 98 1.85 (0.92-3.70) .08
No 119 1 [Reference] 402 1 [Reference]
Different than it used to be
Yes 65 0.78 (0.37-1.66) .52 186 0.77 (0.48-1.25) .30
No 80 1 [Reference] 314 1 [Reference]
Change in
thickness/elevation
Yes 83 0.45 (0.21-0.96) .04d 148 0.20 (0.12-0.34) <.001d
No 62 1 [Reference] 352 1 [Reference]
Onset of pain
Yes 22 0.21 (0.05-0.96) .04d 35 0.28 (0.13-0.61) .001d
No 123 1 [Reference] 465 1 [Reference]
Onset of itching
Yes 43 0.56 (0.23-1.40) .22 103 0.50 (0.27-0.82) .008d
No 102 1 [Reference] 397 1 [Reference]
Onset of bleeding
Yes 43 0.42 (0.17-1.06) .07 51 0.19 (0.10-0.36) <.001d
No 102 1 [Reference] 449 1 [Reference]
Not applicable or
never noticed
Yes 12 0.53 (0.11-2.52) .42 80 3.51 (1.45-8.46) .005d
No 199 1 [Reference] 422 1 [Reference]
Lesion colori
Pigmented 97 1.16 (0.48-2.85) .74 44 1.53 (0.73-3.23) .26
Don’t know 13 0.23 (0.03-2.12) .20 42 4.36 (1.23-15.45) .02d
Pink/skin colored 33 1 [Reference] 436 1 [Reference]
(continued)
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andfrontofarms) (OR,2.59;95%CI, 1.58-4.23),difficult to self-
examine (neck, upper shoulders, upperback, lowerback, back
of legs and arms) (OR, 2.82; 95% CI, 1.69-4.71), or very diffi-
cult to self-examine (scalp andbottomof feet) (OR, 3.28; 95%
CI, 1.73-6.21). Self-detected clinical warning signs (eg, eleva-
tion,onsetofpain, itching, andbleeding)weremarkersof thick
SSM (Table 2).
Receiving a whole-body PSEwas associatedwith thinner
SSM (OR, 2.25; 95%CI, 1.16-4.35) (Table 3). Therewere no sig-
nificantassociationsofpatientattitudesandperceptionsabout
melanoma with thinner SSM (Table 4).
A secondary analysis using a cutoff of 1mmor less for the
definition of thinner SSM showed similar statistically signifi-
cant results (data not shown).
Mode of ThinnerMelanomaDetection
According to SSE and PSE Practices
The majority of all patients with NM and SSM (53%) first no-
ticed theirmelanomacomparedwith thosewhose tumorswere
detectedbyspouses,partners, family, friends,andothers (28%)
or aphysician (19%).Whenexamining tumor thickness by the
person who first noticed the melanoma, patient detection of
melanoma was not associated with thinner tumors. How-
ever, detection ofmelanoma by amedical provider was asso-
ciatedwith thinner SSM (OR, 2.48; 95% CI, 1.14-5.40) but not
with thinner NM (OR, 1.77; 95% CI, 0.52-6.01) (Table 2).
Skin self-examination is successful when it leads to de-
tection of early melanoma. Among the 107 patients with NM
who performed SSE, 67 (63%) self-detected their melanoma;
however, only 22 (33%)of thepatientswho self-detected their
melanoma were able to self-detect an NM less than or equal
to2mminthickness (P = .60).Amongthe89patientswhoself-
detectedNM(3patients hadmissingdata), only 24 (27%) self-
detected thinnerNM.Among the24patientswith thinnerNM,
most performed SSE (n = 22; 92%) comparedwith those who
didnotperformSSE (n = 2;8%) (P = .03).This implies that self-
detection of thinner NM was achieved primarily through
regular SSE, even though theoverall rates of successful SSE for
NMwere low.
Discussion
For skin cancer screening, PSE and SSE practices are comple-
mentary approaches that may reduce melanoma-associated
morbidityandmortality.7,21,22Our study investigatedPSE,SSE,
andpatient attitudes related to thedetectionof thinnermela-
noma and explored differences in patients with SSM vs NM.
Our pooled analysis of data from expert centers in 3 different
countries focused for the first time on NM, the most com-
monly fatal melanoma subtype. For our primary study out-
come, a cutoff of less than or equal to a Breslow thickness of
2 mm was selected for thinner NM, as there were only 4 NM
measuring 1 mm or less, precluding any meaningful analysis
in this thickness group. This fact highlights the challenge of
detecting thin NM, due to their small size, morphology that
oftendoesnot follow theABCD (asymmetry, border irregular-
ity, color variation, and diameter >6 mm) criteria, and the
higher growth rate and tumor kinetics compared with
SSM.12,13,15 Recent survival data published in the new Ameri-
canJointCommitteeonCancerclassificationdemonstratesimi-
lar 5-year survival rates for T1 and T2 melanomas, ie, 5-year
Table 2. Multivariate Logistic Regression Analysis of Patient Skin Self-Examination Practices
AssociatedWithMelanoma Thickness in PatientsWith NMor SSM (continued)
Variable
Patients With NM (n = 147) Patients With SSM (n = 538)
Patients,
No.
Tumor ≤2 mm,
OR (95% CI)a P Value
Patients,
No.
Tumor ≤2 mm,
OR (95% CI)b P Value
Could patient easily see
the lesion?j
Yes 108 2.32 (0.86-6.21) .10 325 0.66 (0.40-1.08) .10
No/don’t know 37 1 [Reference] 197 1 [Reference]
How often patient carefully
examined their molesi
Every 1-2 mo/every 6 mo 40 1.36 (0.60-3.08) .46 153 1.49 (0.84-2.62) .17
Every year 16 0.61 (0.16-2.38) .48 81 0.82 (0.43-1.55) .54
Never 88 1 [Reference] 295 1 [Reference]
Had patient ever noticed
a change in any moles?k
Yes 72 2.62 (1.21-5.67) .02d 295 0.79 (0.50-1.26) .33
No 74 1 [Reference] 237 1 [Reference]
When patient first became
concerned about the lesionk
Only at time of diagnosis 37 2.07 (0.52-8.31) .30 180 1.07 (0.45-2.52) .89
<4 mo before diagnosis 62 0.77 (0.16-3.71) .74 191 0.47 (0.19-1.15) .10
4-12 mo before diagnosis 34 1.30 (0.28-5.97) .73 109 2.00 (0.81-4.91) .13
1+ years before diagnosis 14 1 [Reference] 51 1 [Reference]
Ever used a melanoma picturei
Yes 23 2.48 (0.98-6.30) .06 112 1.62 (0.83-3.15) .16
No 121 1 [Reference] 417 1 [Reference]
Abbreviations: NM, nodular
melanoma; OR, odds ratio;
SSM, superficial spreading
melanoma.
a Adjusted for age (continuous), sex.
bAdjusted for age (continuous), sex,
education.
c Twelve missing values.
d Statistically significant.
e Nineteenmissing values.
f Included face, front of legs, chest,
stomach, and front of arms.
g Included neck, upper shoulders,
upper back, lower back, back of
legs, and back of arms.
h Included scalp and bottom of feet.
i Sevenmissing values.
j Eighteenmissing values.
k Twenty missing values.
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survival of 99% for T1amelanoma, 99% for T1b, 96% for T2a,
and 93% for T2b.23 These findings support our analysis using
the 2-mm cutoff for the study of thinner NM and SSM.
Most melanomas were first noticed by the patient in our
study, aspreviously reported24-27; however, self-detectiondid
not result in significantly thinner NM or SSM, at least in part
becauseof the fact thatmostpatientswhoself-detectedmela-
noma did not perform regular SSE.
Performing regular SSE was associated with thinner SSM
but not thinner NM. Skin self-examination has been associ-
ated with the detection of thinner melanoma,9,19,24,25,27 and
with reduced melanoma incidence in a population-based
case-control study28 in the United States. Although SSE did
not result in significant rates of thinner NM detection in our
study, those few patients who reported self-detection of
thinner NM achieved this through SSE. Performance of SSE
Table 3. Multivariate Logistic Regression Analysis of Health Care Behaviors AssociatedWithMelanoma Thickness in PatientsWith NMor SSM
Variable
Patients With NM (n = 147) Patients With SSM (n = 538)
Patients,
No.
Tumor ≤2 mm,
OR (95% CI)a P Value
Patients,
No.
Tumor ≤2 mm,
OR (95% CI)b P Value
Had a usual place to go when sick/needed health advicec
No usual place to go for care 116 1 [Reference] 65 1 [Reference]
Doctor’s office/clinic/health center/urgent care
center/emergency department/other
30 1.03 (0.41-2.57) .95 464 2.20 (1.15-4.19) .02d
Had a physician for routine caree
No 54 1 [Reference] 392 1 [Reference]
Yes 93 1.34 (0.61-2.93) .47 137 1.71 (1.01-2.89) .04d
Visits to physician in the year before patient
was diagnosed with melanomac
0 22 1 [Reference] 63 1 [Reference]
1 38 1.42 (0.38-5.32) .60 136 0.88 (0.40-1.95) .76
2-3 44 2.70 (0.77-9.45) .12 174 1.35 (0.61-3.01) .46
>3 42 1.63 (0.44-5.95) .46 156 1.51 (0.67-3.41) .33
Patient received a physician skin examination for cancerf
No/don’t know 83 1 [Reference] 266 1 [Reference]
Yes 59 2.21 (1.04-4.69) .04d 252 1.53 (0.96-2.46) .08
If patient had a physician examine skin for cancer,
what was the reason for examination?f
Part of physician’s routine physical examination
No 122 1 [Reference] 419 1 [Reference]
Yes 19 2.26 (0.81-6.30) .12 98 1.18 (0.65-2.15) .58
Physician told patient he or she should be screened
for skin cancer
No 132 1 [Reference] 480 1 [Reference]
Yes 9 6.27 (1.46-26.88) .01d 37 1.42 (0.52-3.85) .49
Patient was concerned about skin cancer
No 130 1 [Reference] 471 1 [Reference]
Yes 11 3.86 (1.05-14.23) .04d 46 0.91 (0.40-2.08) .82
Patient’s spouse, partner, or other person thought
patient should be screened
No 133 1 [Reference] 485 1 [Reference]
Yes 8 5.08 (1.13-22.73) .03d 32 0.89 (0.34-2.31) .81
Type of skin examination performed by physiciang
None 86 1 [Reference] 269 1 [Reference]
Whole skin 26 2.67 (1.05-6.82) .04d 125 2.25 (1.16-4.35) .02d
Particular lesion 28 1.73 (0.67-4.49) .26 112 1.17 (0.66-2.10) .59
Don’t know 2 4.23 (0.25-72.67) .32 13 0.46 (0.13-1.54) .21
Did physician tell patient he or she was at risk
for skin cancer?
No 117 1 [Reference] 402 1 [Reference]
Yes 30 5.32 (2.26-12.53) <.001d 127 1.98 (1.06-3.71) .03d
Abbreviations: NM, nodular melanoma; OR, odds ratio; SSM, superficial
spreadingmelanoma.
a Adjusted for age (continuous), sex.
bAdjusted for age (continuous), sex, education.
c Twelve missing values.
d Statistically significant.
e Nineteenmissing values.
f Sevenmissing values.
g Eighteenmissing values.
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does not ensure that patients will be able to self-detect thin-
ner NM, as opposed to thicker NM that may exhibit more
obvious detectable changes, such as bleeding, ulceration,
and elevation.29,30 In this study, no self-recognized clinical
changes of the lesion were associated with the detection of
thinner NM, with the exception of patients who noticed a
change in any of their moles, affirming the value of educat-
ing patients and providers regarding the outlier phenom-
enon and the need to seek prompt medical attention for a
changing lesion. Both the “ugly duckling” rule and the addi-
tion of E (for evolving) have provided important clinical
warning signs to improve the recognition of NM.31-35 Our
findings support the importance of educating individuals on
SSE practices, including thoroughness and frequency,19,36
and highlight the need for complementary practices such as
PSE for the detection of thinner NM.
Physician detection of melanoma is associated with
detection of thinner melanoma.24,26 Whole-body PSE in the
year before melanoma diagnosis was associated with a 2.5-
fold increased probability of thin melanoma detection in US
patients.8 A population-based, case-control study in Austra-
lia reported that whole-body PSE was associated with a 38%
higher probability of being diagnosed with a thin melanoma
(≤0.75 mm).37 A risk-stratified approach to skin cancer
screening with whole-body examination by a dermatologist,
supported by total-body photography and sequential digital
dermoscopy imaging, was effective for the early detection of
melanoma in a prospective 5-year study.38,39 Notably, in our
study, whole-body PSE was associated with more than a
2-fold increased likelihood of detection of thinner tumors
for both SSM and NM, while the examination of only a par-
ticular lesion was not. Physician examination may have an
indirect effect on thinner melanoma detection by increasing
overall patient awareness rather than focusing on a specific
suspicious lesion. Training of physicians focusing on whole-
body PSE for skin cancer, possibly with the assistance of der-
moscopy, smart phone applications, or even artificial intelli-
gence, may enhance thinner NM detection.40
Table 4. Multivariate Logistic Regression Analysis of Attitudes AboutMelanoma AssociatedWith Tumor Thickness
in PatientsWith NMor SSM Subtypes
Variable
Patients With NM (n = 147) Patients With SSM (n = 538)
Patients, No. (With
≤2 mm/>2 mm
Tumor, No.)
Tumor ≤2 mm,
Odds Ratio
(95% CI)a P Value
Patients, No. (With
≤2 mm/>2 mm
Tumor, No.)
Tumor ≤2 mm,
Odds Ratio
(95% CI)b P Value
Took interest in reading about skin cancer detectionc
Disagree/strongly disagree 82 (14/68) 1 [Reference] 268 (208/60) 1 [Reference]
Agree/strongly agree 32 (14/18) 4.20 (1.62-10.87) .003d 125 (109/16) 1.91 (1.03-3.54) .04
Neither agree nor disagree 32 (12/20) 3.28 (1.27-8.47) .01d 139 (117/22) 1.49 (0.86-2.61) .16
Important to look at skin for signs of melanomae
Disagree/strongly disagree 64 (7/57) 1 [Reference] 198 (108/32) 1 [Reference]
Agree/strongly agree 56 (22/34) 5.52 (2.09-14.58) .001d 194 (168/26) 1.62 (0.93-2.80) .09
Neither agree nor disagree 26 (11/15) 6.86 (2.19-21.50) .001d 139 (113/26) 1.26 (0.72-2.20) .42
Important to have a health care professional
examine skin for signs of melanomae
Disagree/strongly disagree 60 (8/52) 1 [Reference] 140 (108/32) 1 [Reference]
Agree/strongly agree 66 (25/41) 4.10 (1.65-10.16) .002d 287 (239/48) 1.47 (0.87-2.51) .15
Neither agree nor disagree 20 (7/13) 3.57 (1.08-11.78) .04d 104 (86/18) 1.52 (0.78-2.96) .22
Comfortable having a family member look at molesf
Disagree/strongly disagree 36 (3/33) 1 [Reference] 100 (78/22) 1 [Reference]
Agree/strongly agree 73 (26/47) 6.32 (1.75-22.76) .005d 297 (248/49) 1.39 (0.77-2.49) .28
Neither agree nor disagree 35 (10/25) 4.70 (1.15-19.11) .03d 126 (104/22) 1.39 (0.70-2.76) .35
Comfortable undressing for a skin examination
by a health care professionalg
Disagree/strongly disagree 37 (3/34) 1 [Reference] 140 (109/31) 1 [Reference]
Agree/strongly agree 86 (33/53) 7.09 (2.01-24.99) .002d 308 (255/53) 1.31 (0.78-2.20) .30
Neither agree nor disagree 22 (4/18) 2.57 (0.52-12.80) .25 82 (69/13) 1.40 (0.67-2.94) .37
Patient never thought of self at risk for melanomah
Disagree/strongly disagree 25 (10/15) 1 [Reference] 126 (113/13) 1 [Reference]
Agree/strongly agree 107 (20/87) 0.36 (0.14-0.94) .04d 323 (252/71) 0.53 (0.28-1.02) .06
Neither agree nor disagree 14 (10/4) 4.29 (1.01-18.19) .048d 84 (70/14) 0.61 (0.27-1.40) .24
Abbreviations: NM, nodular melanoma; SSM, superficial spreadingmelanoma.
a Adjusted for age (continuous), sex.
bAdjusted for age (continuous), sex, education.
c Twelve missing values.
d Statistically significant.
e Nineteenmissing values.
f Sevenmissing values.
g Eighteenmissing values.
h Twenty missing values.
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Behavioralandattitudinalpredispositionsandintentionsto
performapractice (such as receipt of screening)maybe strong
indicators of one’s actual practice. In our study, patients diag-
nosedwiththinnerNMweremore likelythanpatientswiththick
NM to read about skin cancer, express the importance of look-
ingat theskinforsignsofmelanoma,andhaveahealthcarepro-
fessional examine the skin, suggesting that awareness canbea
behavioral driver for earlier discovery of NM.
Limitations
Study limitations include possible reporting and recall bias of
the frequencyor completeness of SSEandPSEpractices in the
year prior to diagnosis. The statistically significant differ-
ences in awareness inpatientswith thinnerNMhadverywide
confidence intervals because few patients had thinner NM
acrosscategories,andshouldthereforebe interpretedwithcau-
tion. Also, a relatively small number of thinner NM were in-
cluded; other studiesofNMhavealsobeenhamperedby small
sample sizes, emphasizing the need for expanded investiga-
tion of larger cohorts with more thin and thick NM.
Conclusions
Our pooled analysis shows that receipt of a whole-body PSE
in the year before diagnosis was associated with diagnosis of
thinner NM, while recognition of clinical changes in the le-
sion was not. Routine SSE was associated with the detection
of thinnerSSMbutnot thinnerNM,althoughsignificantlymore
patients who performed SSE succeeded in self-detection of
thinner NM than those who did not perform SSE. These find-
ingsunderscore thechallengesofearlyNMdetectionandhigh-
light the importance of complementary practices that in-
cluderegularwhole-bodyPSEand increasedpatientandfamily
awareness and education about SSE and PSE practices to pro-
mote earlier detection of NM and SSM.
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